Damora Therapeutics, Inc.
DMRA
$20.96
$0.050.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 61.87% | -7.75% | -38.95% | -33.63% | -28.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 370.91% | 116.38% | -41.00% | -43.28% | -52.08% |
| Operating Income | -370.91% | -116.38% | 41.00% | 43.28% | 52.08% |
| Income Before Tax | -1,173.57% | -880.41% | 24.99% | 34.65% | 40.15% |
| Income Tax Expenses | 109.30% | 21.95% | -104.08% | -88.10% | -- |
| Earnings from Continuing Operations | -1,171.09% | -878.77% | 25.17% | 34.74% | 40.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,171.09% | -878.77% | 25.17% | 34.74% | 40.01% |
| EBIT | -370.91% | -116.38% | 41.00% | 43.28% | 52.08% |
| EBITDA | -371.47% | -116.52% | 40.99% | 42.75% | 51.73% |
| EPS Basic | -820.45% | -670.43% | 37.90% | 44.40% | 46.50% |
| Normalized Basic EPS | -113.87% | -74.33% | 52.67% | 51.33% | 57.56% |
| EPS Diluted | -820.45% | -670.43% | 37.90% | 44.40% | 46.50% |
| Normalized Diluted EPS | -113.87% | -74.33% | 52.67% | 51.33% | 57.56% |
| Average Basic Shares Outstanding | 689.81% | 17.80% | 20.17% | 17.65% | 12.94% |
| Average Diluted Shares Outstanding | 689.81% | 17.80% | 20.17% | 17.65% | 12.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |